MorphoSys (MOR) Competitors $18.96 0.00 (0.00%) As of 05/21/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock MOR vs. VTRS, MRNA, ASND, QGEN, ROIV, RVMD, ELAN, BPMC, BBIO, and VRNAShould you be buying MorphoSys stock or one of its competitors? The main competitors of MorphoSys include Viatris (VTRS), Moderna (MRNA), Ascendis Pharma A/S (ASND), Qiagen (QGEN), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Elanco Animal Health (ELAN), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), and Verona Pharma (VRNA). These companies are all part of the "pharmaceutical products" industry. MorphoSys vs. Viatris Moderna Ascendis Pharma A/S Qiagen Roivant Sciences Revolution Medicines Elanco Animal Health Blueprint Medicines BridgeBio Pharma Verona Pharma MorphoSys (NASDAQ:MOR) and Viatris (NASDAQ:VTRS) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, community ranking, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings. Which has preferable earnings and valuation, MOR or VTRS? Viatris has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMorphoSys$238.28M11.99-$205.35M-$3.48-5.45Viatris$14.33B0.70$54.70M-$3.17-2.68 Is MOR or VTRS more profitable? Viatris has a net margin of -5.87% compared to MorphoSys' net margin of -226.79%. Viatris' return on equity of 16.46% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets MorphoSys-226.79% -694.31% -22.55% Viatris -5.87%16.46%7.09% Do analysts recommend MOR or VTRS? Viatris has a consensus price target of $10.50, indicating a potential upside of 23.53%. Given Viatris' stronger consensus rating and higher probable upside, analysts plainly believe Viatris is more favorable than MorphoSys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Viatris 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75 Does the MarketBeat Community prefer MOR or VTRS? MorphoSys received 2 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 38.46% of users gave MorphoSys an outperform vote while only 34.85% of users gave Viatris an outperform vote. CompanyUnderperformOutperformMorphoSysOutperform Votes2538.46% Underperform Votes4061.54% ViatrisOutperform Votes2334.85% Underperform Votes4365.15% Do institutionals & insiders believe in MOR or VTRS? 18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Comparatively, 0.1% of Viatris shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media refer more to MOR or VTRS? In the previous week, Viatris had 31 more articles in the media than MorphoSys. MarketBeat recorded 31 mentions for Viatris and 0 mentions for MorphoSys. MorphoSys' average media sentiment score of 0.00 beat Viatris' score of -0.02 indicating that MorphoSys is being referred to more favorably in the media. Company Overall Sentiment MorphoSys Neutral Viatris Neutral Which has more volatility & risk, MOR or VTRS? MorphoSys has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, Viatris has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. SummaryViatris beats MorphoSys on 12 of the 18 factors compared between the two stocks. Get MorphoSys News Delivered to You Automatically Sign up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MOR vs. The Competition Export to ExcelMetricMorphoSysPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.86B$6.48B$5.33B$8.39BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-5.459.0626.7119.71Price / Sales11.99251.48386.12120.59Price / CashN/A65.8538.2534.62Price / Book54.176.456.774.50Net Income-$205.35M$143.98M$3.23B$248.22M7 Day PerformanceN/A2.41%1.80%0.56%1 Month PerformanceN/A4.56%11.10%13.17%1 Year Performance3.61%-2.67%17.11%7.30% MorphoSys Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730VTRSViatris1.9121 of 5 stars$8.76-0.9%$10.50+19.9%-22.6%$10.28B$14.33B-11.8437,000Trending NewsGap UpMRNAModerna4.4441 of 5 stars$26.39+6.2%$53.95+104.4%-82.0%$10.21B$3.14B-2.843,900Trending NewsAnalyst ForecastHigh Trading VolumeASNDAscendis Pharma A/S3.3608 of 5 stars$160.33+1.7%$216.07+34.8%+28.7%$9.78B$368.70M-22.58640QGENQiagen3.9868 of 5 stars$42.77+0.3%$48.42+13.2%-3.5%$9.51B$2.00B119.096,030Positive NewsROIVRoivant Sciences2.1287 of 5 stars$10.84+0.5%$17.50+61.4%-2.8%$7.73B$122.59M-72.26860Positive NewsUpcoming EarningsRVMDRevolution Medicines4.36 of 5 stars$39.93+1.0%$67.08+68.0%-2.3%$7.44B$742,000.00-11.12250Positive NewsELANElanco Animal Health3.2265 of 5 stars$13.24+2.5%$15.17+14.6%-24.4%$6.58B$4.43B33.109,800Analyst ForecastGap UpBPMCBlueprint Medicines1.7972 of 5 stars$101.21-0.5%$126.56+25.0%-2.0%$6.54B$562.12M-93.71640Positive NewsInsider TradeBBIOBridgeBio Pharma4.5971 of 5 stars$33.69-0.4%$57.09+69.5%+12.2%$6.40B$127.42M-11.82400Insider TradeVRNAVerona Pharma2.6645 of 5 stars$72.58+1.8%$81.50+12.3%+492.7%$5.88B$118.54M-37.8030Positive NewsGap Down Related Companies and Tools Related Companies VTRS Competitors MRNA Competitors ASND Competitors QGEN Competitors ROIV Competitors RVMD Competitors ELAN Competitors BPMC Competitors BBIO Competitors VRNA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MOR) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MorphoSys AG Please log in to your account or sign up in order to add this asset to your watchlist. Share MorphoSys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MOR Stock Free MOR Stock Alerts